Hepatitis B in pregnancy: screening, treatment, and prevention of vertical transmission

Publications & Guidelines, Obstetric Care Consensus,
  • The diagnosis of the chronic carrier state is confirmed with persistence of HBsAg and the absence of hepatitis B surface antibody (HBsAb).
  • HBsAg and HBsAb do not coexist.
    Start with maternal HBsAg.
  • HBV core ab is produced secondary to infection (never from immunization).

In the United States, vertical transmission is responsible for up to 50% of HBV infection worldwide.o In pregnancy, prevalence 0.7-0.9% for chronic HBV


HBV viral load in the third trimester (28-32 weeks)
If> 6-8 log 10 copies /mL – antiretroviral Rx to decrease risk of intrauterine transmission
To convert viral load from IU/mL to copies /mL multiply x5.6
Tenofovir (first line) 300 mg/day till delivery
Lamivudine (high rate of resistance) if used as a single agent
Indications for antiretroviral: Copies > 106-8; Pos HBeAg
The use of lamivudine and tenofovir in the postpartum period is not currently recommended solely for HBV prevention until additional data are available.

Download PDF    Download Slides     Patient Education

BabyCenter     Podcast

Last Reaffirmed: Aug 1, 2020

TAGS:screening, prevention, hepatitis b
CATEGORIES:Internal Medicine & Medicine Subspecialists Family Medicine OB-GYN, Sub-specialist, Certified Nurse Midwife and Laborist Maternal Medical Complications